Company profile: GH Research
1.1 - Company Overview
Company description
- Provider of clinical-stage 5-MeO-DMT (mebufotenin) therapies for psychiatric and neurological disorders, initially focused on treatment-resistant depression: GH001 inhalation (Phase 2b TRD; Phase 2a bipolar II and postpartum depression), GH002 intravenous (completed Phase 1), and GH003 intranasal (preclinical).
Products and services
- GH003: Mebufotenin-based intranasal therapy in preclinical development for psychiatric or neurological disorders, utilizing an intranasal administration route and designated preclinical
- GH002: Mebufotenin-based intravenous therapy that has completed Phase 1 trials for psychiatric or neurological disorders, administered intravenously and classified Phase 1–completed
- GH001: Mebufotenin-based inhalation therapy in Phase 2b trials for treatment-resistant depression and Phase 2a trials for bipolar II disorder and postpartum depression, designated clinical-stage
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to GH Research
JuvLabs
HQ: Isle of Man
Website
- Description: Provider of biotech therapies and products to modify aging and address age-related diseases. Through its JuvRx therapeutics division, the company develops novel treatments targeting fibrosis and inflammatory conditions, including serpin-based PAI-1 inhibitors, TGF-β modulation drugs, NAD+ metabolism enhancers (with the Buck Institute), ketone-based therapies for heart failure, and an oral plasmalogen precursor to restore cell function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JuvLabs company profile →
MAP Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel inhalation therapies under development for respiratory and systemic diseases, with proprietary product candidates including Unit Dose Budesonide for pediatric asthma (children six months to eight years) and MAP0004 for migraine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MAP Pharmaceuticals company profile →
Magstim
HQ: United Kingdom
Website
- Description: Provider of Transcranial Magnetic Stimulation (TMS) stimulators and packages for Magstim TMS therapy and neuromodulation research. Offers Magstim TMS Therapy for depression, StimGuide for precise TMS delivery, and Neurosign intraoperative nerve monitoring solutions. Provides installation, certification training, and dedicated engineering service and support. Magstim stimulators are used in the majority of published TMS research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Magstim company profile →
Tris Pharma
HQ: United States
Website
- Description: Provider of specialty generic pharmaceuticals leveraging its LiquiXR drug delivery technology for sustained-release formulations, including ADHD treatments with flexible dosing for patients aged 6+, a portfolio of 10 generic products with 20+ in development, technology licensing of its delivery technologies, and partnerships to enhance product development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tris Pharma company profile →
Satsuma Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development for migraine, advancing STS101, a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine (DHE) for the acute treatment of migraine, self-administered via a pre-filled, single-use nasal delivery device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satsuma Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for GH Research
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to GH Research
2.2 - Growth funds investing in similar companies to GH Research
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for GH Research
4.2 - Public trading comparable groups for GH Research
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →